Related Experiment Video
Updated: Oct 7, 2025

Assessment of Cellular Bioenergetics in Mouse Hematopoietic Stem and Primitive Progenitor Cells using the Extracellular Flux Analyzer
Published on: September 24, 2021
Loss of SDHB Induces a Metabolic Switch in the hPheo1 Cell Line toward Enhanced OXPHOS
Mouna Tabebi1, Ravi Kumar Dutta1, Camilla Skoglund1
1Department of Biomedical and Clinical Sciences (BKV), Linköping University, 581 83 Linköping, Sweden.
Background:
Enzymes of tricarboxylic acid (TCA) have recently been recognized as tumor suppressors. Mutations in the SDHB subunit of succinate dehydrogenase (SDH) cause pheochromocytomas and paragangliomas (PCCs/PGLs) and predispose patients to malignant disease with poor prognosis.
Methods:
Using the human pheochromocytoma cell line (hPheo1), we knocked down SDHB gene expression using CRISPR-cas9 technology.
Results:
Microarray gene expression analysis showed that >500 differentially expressed gene targets, about 54%, were upregulated in response to SDHB knock down. Notably, genes involved in glycolysis, hypoxia, cell proliferation, and cell differentiation were up regulated, whereas genes involved in oxidative phosphorylation (OXPHOS) were downregulated. In vitro studies show that hPheo1 proliferation is not affected negatively and the cells that survive by shifting their metabolism to the use of glutamine as an alternative energy source and promote OXPHOS activity. Knock down of SDHB expression results in a significant increase in GLUD1 expression in hPheo1 cells cultured as monolayer or as 3D culture. Analysis of TCGA data confirms the enhancement of GLUD1 in SDHB mutated/low expressed PCCs/PGLs.
Conclusions:
Our data suggest that the downregulation of SDHB in PCCs/PGLs results in increased GLUD1 expression and may represent a potential biomarker and therapeutic target in SDHB mutated tumors and SDHB loss of activity-dependent diseases.
Insights
Succinate dehydrogenase B (SDHB) mutations in pheochromocytomas and paragangliomas (PCCs/PGLs) increase GLUD1 expression. This suggests GLUD1 may be a therapeutic target for SDHB-deficient tumors.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- Tricarboxylic acid (TCA) cycle enzymes are emerging tumor suppressors.
- Mutations in succinate dehydrogenase B (SDHB) are linked to pheochromocytomas/paragangliomas (PCCs/PGLs) and poor prognosis.
Purpose of the Study:
- To investigate the molecular consequences of SDHB downregulation in PCCs/PGLs.
- To identify potential biomarkers and therapeutic targets in SDHB-deficient tumors.
Main Methods:
- CRISPR-cas9 technology was used to knock down SDHB gene expression in the hPheo1 human pheochromocytoma cell line.
- Microarray gene expression analysis and TCGA data analysis were performed.
Main Results:
- SDHB knockdown upregulated genes involved in glycolysis, hypoxia, and proliferation, while downregulating oxidative phosphorylation (OXPHOS) genes.
- Cells adapted by utilizing glutamine for energy and promoting OXPHOS.
- SDHB knockdown significantly increased GLUD1 expression, confirmed in TCGA data for SDHB-mutated PCCs/PGLs.
Conclusions:
- Downregulation of SDHB in PCCs/PGLs leads to increased GLUD1 expression.
- GLUD1 represents a potential biomarker and therapeutic target for SDHB-mutated tumors and diseases with SDHB loss of activity.
Related Concept Videos
Other Glycolytic Pathways
Peroxisomes

